{"id":45229,"date":"2026-01-17T02:21:00","date_gmt":"2026-01-16T19:21:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=45229"},"modified":"2026-01-17T02:21:00","modified_gmt":"2026-01-16T19:21:00","slug":"first-u-s-patient-dosed-in-bipass-phase-3-prostate-cancer-diagnosis-study","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=45229","title":{"rendered":"First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

MELBOURNE, Australia\u00a0and INDIANAPOLIS<\/span>, Jan. 16, 2026<\/span> \/PRNewswire\/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS\u2122 (Bi<\/b>opsy of the P<\/b>rostate A<\/b>voidance S<\/b>tratification S<\/b>tudy), a<\/span> Phase 3 trial to \u00a0evaluate the use of Telix’s commercial PSMA-PET[1]<\/sup> imaging agents, Illuccix\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting.\u00a0The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies.<\/p>\n

\n<\/div>\n

BiPASS\u2122 is the first study designed to gain marketing authorization for 68<\/sup>Ga-PSMA-PET[2]<\/sup> imaging in the pre-biopsy setting. The prospective, open-label Phase 3 trial will enroll 250 patients across sites in the U.S. and Australia. The study aims to determine whether combining MRI[3]<\/sup> with Illuccix\/Gozellix 68<\/sup>Ga-PSMA-11 PET can improve diagnostic accuracy and reduce unnecessary biopsies compared to current standard practice. Men with elevated PSA[4]<\/sup> often proceed from an inconclusive MRI to template prostate biopsy. This procedure is stressful and unpleasant, can lead to complications[5]<\/sup> and frequently proves to be of no benefit to the patient[6]<\/sup>.<\/p>\n

In the U.S., more than one million prostate biopsies are performed annually, yet up to 75% are negative[6]<\/sup>, and one in four patients declines the physician recommendation of receiving a biopsy[7]<\/sup>. The objective of BiPASS\u2122 is to demonstrate improved lesion detection and patient stratification by integrating non-invasive molecular Illuccix\/Gozellix 68<\/sup>Ga-PSMA-11 PET imaging early in the diagnostic pathway, to enable biopsy de-escalation or, alternatively, greater biopsy precision when administered.<\/p>\n

If the BiPASS\u2122 study achieves its primary objectives, it could lead to a reduction in unnecessary biopsies, improved patient experience, and a significant expansion of access to precision imaging for patients with suspected prostate cancer, potentially increasing the use of 68<\/sup>Ga-PSMA-11 PET\u00a0in a large new patient population.<\/p>\n

Dr. Mazzarella, Vice President of Research for Urology America,\u00a0said, “We’re excited to participate in the BiPASS trial at Urology Austin, which brings together promising technologies and emerging trends in patient care. \u00a0If BiPASS is successful in meeting its primary endpoint, it could eliminate the need for biopsy\u2014reducing risks, side effects, and costs\u2014and improve decision-making for providers and patients.”<\/p>\n

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, added, “Illuccix and Gozellix are already transforming how clinicians treat and manage prostate cancer. By initiating this trial, we are reinforcing Telix’s commitment to patient centricity, clinical innovation, and industry leadership\u2014with the goal of eliminating invasive biopsy.”<\/p>\n

About BiPASS\u2122<\/b><\/p>\n

BiPASS\u2122 (ClinicalTrials.gov ID: NCT07052214<\/a>) leverages promising clinical findings from the PRIMARY[8]<\/sup> and PRIMARY2[9]<\/sup> studies, which demonstrated that MRI combined with 68<\/sup>Ga-PSMA-11 PET can better define or rule out prostate cancer and guide active surveillance before invasive biopsy. Professor Louise Emmett, Principal Investigator for PRIMARY, serves on the BiPASS\u2122 Steering Committee and as an Investigator on the study.<\/p>\n

About Illuccix\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection) <\/b><\/p>\n

Illuccix, after radiolabeling with 68<\/sup>Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level, and for selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products.<\/p>\n

About Gozellix\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection) <\/b><\/p>\n

Gozellix, after radiolabeling with 68<\/sup>Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, and those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.<\/p>\n

About Telix Pharmaceuticals Limited <\/b><\/p>\n

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).<\/p>\n

Illuccix, Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix has been approved by the U.S. FDA[10]<\/sup>. Illuccix and Gozellix have not received regulatory approval for initial diagnosis of prostate cancer in any jurisdiction.<\/p>\n

Visit www.telixpharma.com<\/a> for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn<\/a>, X<\/a> and Facebook<\/a>.<\/p>\n

Telix Investor Relations<\/b><\/p>\n

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com<\/a><\/p>\n

Telix Investor Relations (U.S.)\u202f\u00a0<\/b><\/p>\n

Annie Kasparian\u202f
Telix Pharmaceuticals Limited\u202f
Director Investor Relations and Corporate Communications\u202f
Email: annie.kasparian@telixpharma.com<\/a>\u00a0<\/p>\n

Media Contact<\/b><\/p>\n

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com<\/a><\/p>\n

Legal Notices<\/b><\/p>\n

Cautionary Statement Regarding Forward-Looking Statements.\u00a0<\/i><\/p>\n

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.<\/i><\/p>\n

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. \u202fTo the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.<\/i><\/p>\n

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.<\/i><\/p>\n

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the \u00ae or \u2122 symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.<\/i><\/p>\n

\u00a92026 Telix Pharmaceuticals Limited. All rights reserved.<\/i><\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

[1] Imaging of prostate-specific membrane antigen with positron emission tomography.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[2]\u00a0Positron emission tomography.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[3]\u00a0Magnetic resonance imaging.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[4]\u00a0Prostate-specific antigen.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[5]\u00a0Durkan G et al. Prostate Cancer Prostatic Dis.<\/i>\u00a02000.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[6]\u00a0Vickers et al. J Clin Oncol. 2010.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[7]\u00a0Schaufler C et al.\u00a0Urologic Oncology: Seminars and Original Investigations<\/i>. 2022.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[8]\u00a0Emmett et al., Eur Urol. <\/i>2021.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[9]\u00a0ClinicalTrials.gov ID: NCT05154162<\/a>. Sponsor: Peter MacCallum Cancer Centre, Australia.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[10]\u00a0Telix ASX disclosure 21 March 2025.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

MELBOURNE, Australia\u00a0and INDIANAPOLIS<\/span>, Jan. 16, 2026<\/span> \/PRNewswire\/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS\u2122 (Bi<\/b>opsy of the P<\/b>rostate A<\/b>voidance S<\/b>tratification S<\/b>tudy), a<\/span> Phase 3 trial to \u00a0evaluate the use of Telix’s commercial PSMA-PET[1]<\/sup> imaging agents, Illuccix\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting.\u00a0The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies.<\/p>\n

\n<\/div>\n

BiPASS\u2122 is the first study designed to gain marketing authorization for 68<\/sup>Ga-PSMA-PET[2]<\/sup> imaging in the pre-biopsy setting. The prospective, open-label Phase 3 trial will enroll 250 patients across sites in the U.S. and Australia. The study aims to determine whether combining MRI[3]<\/sup> with Illuccix\/Gozellix 68<\/sup>Ga-PSMA-11 PET can improve diagnostic accuracy and reduce unnecessary biopsies compared to current standard practice. Men with elevated PSA[4]<\/sup> often proceed from an inconclusive MRI to template prostate biopsy. This procedure is stressful and unpleasant, can lead to complications[5]<\/sup> and frequently proves to be of no benefit to the patient[6]<\/sup>.<\/p>\n

In the U.S., more than one million prostate biopsies are performed annually, yet up to 75% are negative[6]<\/sup>, and one in four patients declines the physician recommendation of receiving a biopsy[7]<\/sup>. The objective of BiPASS\u2122 is to demonstrate improved lesion detection and patient stratification by integrating non-invasive molecular Illuccix\/Gozellix 68<\/sup>Ga-PSMA-11 PET imaging early in the diagnostic pathway, to enable biopsy de-escalation or, alternatively, greater biopsy precision when administered.<\/p>\n

If the BiPASS\u2122 study achieves its primary objectives, it could lead to a reduction in unnecessary biopsies, improved patient experience, and a significant expansion of access to precision imaging for patients with suspected prostate cancer, potentially increasing the use of 68<\/sup>Ga-PSMA-11 PET\u00a0in a large new patient population.<\/p>\n

Dr. Mazzarella, Vice President of Research for Urology America,\u00a0said, “We’re excited to participate in the BiPASS trial at Urology Austin, which brings together promising technologies and emerging trends in patient care. \u00a0If BiPASS is successful in meeting its primary endpoint, it could eliminate the need for biopsy\u2014reducing risks, side effects, and costs\u2014and improve decision-making for providers and patients.”<\/p>\n

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, added, “Illuccix and Gozellix are already transforming how clinicians treat and manage prostate cancer. By initiating this trial, we are reinforcing Telix’s commitment to patient centricity, clinical innovation, and industry leadership\u2014with the goal of eliminating invasive biopsy.”<\/p>\n

About BiPASS\u2122<\/b><\/p>\n

BiPASS\u2122 (ClinicalTrials.gov ID: NCT07052214<\/a>) leverages promising clinical findings from the PRIMARY[8]<\/sup> and PRIMARY2[9]<\/sup> studies, which demonstrated that MRI combined with 68<\/sup>Ga-PSMA-11 PET can better define or rule out prostate cancer and guide active surveillance before invasive biopsy. Professor Louise Emmett, Principal Investigator for PRIMARY, serves on the BiPASS\u2122 Steering Committee and as an Investigator on the study.<\/p>\n

About Illuccix\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection) <\/b><\/p>\n

Illuccix, after radiolabeling with 68<\/sup>Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level, and for selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products.<\/p>\n

About Gozellix\u00ae (kit for the preparation of gallium Ga 68 gozetotide injection) <\/b><\/p>\n

Gozellix, after radiolabeling with 68<\/sup>Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, and those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.<\/p>\n

About Telix Pharmaceuticals Limited <\/b><\/p>\n

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).<\/p>\n

Illuccix, Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix has been approved by the U.S. FDA[10]<\/sup>. Illuccix and Gozellix have not received regulatory approval for initial diagnosis of prostate cancer in any jurisdiction.<\/p>\n

Visit www.telixpharma.com<\/a> for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn<\/a>, X<\/a> and Facebook<\/a>.<\/p>\n

Telix Investor Relations<\/b><\/p>\n

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com<\/a><\/p>\n

Telix Investor Relations (U.S.)\u202f\u00a0<\/b><\/p>\n

Annie Kasparian\u202f
Telix Pharmaceuticals Limited\u202f
Director Investor Relations and Corporate Communications\u202f
Email: annie.kasparian@telixpharma.com<\/a>\u00a0<\/p>\n

Media Contact<\/b><\/p>\n

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com<\/a><\/p>\n

Legal Notices<\/b><\/p>\n

Cautionary Statement Regarding Forward-Looking Statements.\u00a0<\/i><\/p>\n

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.<\/i><\/p>\n

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. \u202fTo the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.<\/i><\/p>\n

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.<\/i><\/p>\n

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the \u00ae or \u2122 symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.<\/i><\/p>\n

\u00a92026 Telix Pharmaceuticals Limited. All rights reserved.<\/i><\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

[1] Imaging of prostate-specific membrane antigen with positron emission tomography.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[2]\u00a0Positron emission tomography.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[3]\u00a0Magnetic resonance imaging.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[4]\u00a0Prostate-specific antigen.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[5]\u00a0Durkan G et al. Prostate Cancer Prostatic Dis.<\/i>\u00a02000.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[6]\u00a0Vickers et al. J Clin Oncol. 2010.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[7]\u00a0Schaufler C et al.\u00a0Urologic Oncology: Seminars and Original Investigations<\/i>. 2022.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[8]\u00a0Emmett et al., Eur Urol. <\/i>2021.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[9]\u00a0ClinicalTrials.gov ID: NCT05154162<\/a>. Sponsor: Peter MacCallum Cancer Centre, Australia.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

[10]\u00a0Telix ASX disclosure 21 March 2025.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"class_list":["post-45229","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/45229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45229"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/45229\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}